NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection | Biotech Hunter

Enrollment

195

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

November 24, 2023

Study Completion Date

November 24, 2023

Conditions

Prostatic NeoplasmsProstate Cancer

Interventions

DRUG

[18F]CTT1057

PET/CT imaging with \[18F\]CTT1057

Trial Locations (16)

1211

Novartis Investigative Site, Geneva

6500

Novartis Investigative Site, Bellinzona

13273

Novartis Investigative Site, Marseille

20089

Novartis Investigative Site, Rozzano

20132

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

24127

Novartis Investigative Site, Bergamo

30029

Novartis Investigative Site, Nîmes

31054

Novartis Investigative Site, Toulouse

31059

Novartis Investigative Site, Toulouse

69495

Novartis Investigative Site, Pierre-Bénite

95816

Explorer Molecular Imaging center, Sacramento

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona